Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

;

10/19/2020

Grünenthal has issued notice to AcelRx Pharmaceuticals, Inc. to terminate the supply license agreement for Zalviso™, a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet and delivered through a pre-programmed, non-invasive proprietary delivery device, for the management of acute moderate to severe post-operative pain1 in adult patients in Europe.

The decision to terminate the license agreement comes after careful consideration.  

Terminating the supply of Zalviso™ is not related to any efficacy, safety or clinical concerns.

Further information will be provided directly to healthcare professionals in the coming weeks. We are working to ensure that patients and physicians feel supported during the termination process.

Click here to see Grünenthal’s charter on the responsible use of opioids and click here to access our opioid statement.

1. Zalviso - SUMMARY OF PRODUCT CHARACTERISTICS (SMPC). Available at: https://www.ema.europa.eu/en/documents/product-information/zalviso-epar-product-information_en.pdf